Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Meet Sanofi’s Newest R&D Chief

By Drug Discovery Trends Editor | April 1, 2016

Yong-Jun Liu, M.D., Ph.D. (Credit: Baylor Health Care)A top scientist at AstraZeneca has left the company to join Sanofi.

The French pharmaceutical giant announced on Tuesday that noted immunology specialist Dr. Yong-Jun Liu will join the company as head of research. Liu’s research has yielded numerous important drug targets in areas like allergies and oncology.

He’ll be tasked with leading the charge on all of Sanofi’s research projects and to build a stronger R&D organization. Sanofi’s official statement explains one realm Liu will focus on is rejuvenating the drug maker’s early-stage pipeline.

FierceBiotech adds that Sanofi has had “pretty average financials for a few years now” due to factors like losing patent protection on valuable diabetes drug Lantus. Other medications like cholesterol drug Praluent have shown promise in clinical trials, but Sanofi doesn’t have a potent blockbuster medication to support falling sales.

Elias Zerhouni, Sanofi’s president of global research and development, told Reuters oncology is one priority where Liu’s expertise will be useful. Zerhouni hopes Liu’s arrival will help the company move forward in testing multiple cancer drug combinations and create new approaches for fighting the disease.

Liu’s first day will be on April 1. 

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE